Showing results (21-30 of 419) with videos related to
Sort By:
Pageof 42
Cardiology|November 28, 2014
Predictive value of endostatin in chronic heart failure patients with poor kidney functionThor Ueland, Pål Aukrust, Ståle H Nymo, et al.European Journal of Heart Failure|February 4, 2012
Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiologyKaspar Broch, Thor Ueland, Ståle H Nymo, et al.European Journal of Heart Failure|March 29, 2006
Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF StudyDirk J van Veldhuisen, Halfdan Aass, Dia El Allaf, et al.Circulation. Heart Failure|December 12, 2012
Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)Erik Tandberg Askevold, Ståle Nymo, Thor Ueland, et al.World Journal of Transplantation|March 7, 2018
Importance of physical capacity and the effects of exercise in heart transplant recipientsMarianne Yardley, Lars Gullestad, Kari NytrøenJACC. Heart Failure|March 14, 2014
Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure)Ana Cristina Perez, Pardeep S Jhund, David J Stott, et al.European Journal of Heart Failure|March 15, 2013
CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trialsThor Ueland, Ståle H Nymo, Roberto Latini, et al.Lancet (London, England)|September 21, 2002
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist LosartanKenneth Dickstein, John Kjekshus, Congestive Heart Failure (Greenwich, Conn.)|April 3, 2003
Immunomodulating therapy: new treatment modality in congestive heart failurePål Aukrust, Jan Kristian Damås, Lars GullestadCurrent Opinion in Organ Transplantation|May 3, 2017
Everolimus immunosuppression for renal protection, reduction of allograft vasculopathy and prevention of allograft rejection in de-novo heart transplant recipients: could we have it all?Einar Gude, Lars Gullestad, Arne K AndreassenPageof 42